Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | VenBd in R/R MM: updated analysis of BELLINI

Philippe Moreau • 7 Dec 2019
ASH 2019
Multiple Myeloma Bortezomib Dexamethasone Venetoclax
BELLINI

Philippe Moreau, MD, University Hospital Hôtel-Dieu, Nantes, France, outlines the updated efficacy and safety results of venetoclax in combination with bortezomib and dexamethasone (VenBd) in relapsed/refractory multiple myeloma (MM) from the BELINNI trial (NCT02755597). Prof. Moreau highlights the favorable benefit of venetoclax, particularly in patients with t(11:14) or high expression of BCL-2. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Philippe Moreau

1:15
Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma
Philippe Moreau • 15 Feb 2023
4:49
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy
Philippe Moreau • 15 Feb 2023
3:02
Optimal treatment strategies for multiple myeloma
Philippe Moreau • 10 Sep 2021
1:59
Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau • 10 Sep 2021

Related Videos

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals